High-density lipoproteins during sepsis: from bench to bedside

Critical Care

Alexy Tran-Dinh¹  Philippe Montravers¹  Jacques Duranteau²  Anna Schwendeman³  Olivier Meilhac⁴  Sébastien Tanaka⁴  David Couret⁴ 

[1] AP-HP, Service d’Anesthésie-Réanimation, CHU Bichat-Claude Bernard;AP-HP, Service d’Anesthésie-Réanimation, Hôpitaux Universitaires Paris-Sud, Université Paris-Sud, Hôpital de Bicêtre;Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan;Université de La Réunion, INSERM, UMR 1188 Diabète athérothombose Réunion Océan Indien (DéTROI);

关键词: Endothelium;    High-density lipoprotein (HDL);    Inflammation;    Intensive care unit (ICU);    Lipopolysaccharide (LPS);    Sepsis;   

DOI  :  10.1186/s13054-020-02860-3

来源: DOAJ

【 摘 要 】

Abstract High-density lipoproteins (HDLs) represent a family of particle characterized by the presence of apolipoprotein A-I (apoA-I) and by their ability to transport cholesterol from peripheral tissues back to the liver conferring them a cardioprotective function. HDLs also display pleiotropic properties including antioxidant, anti-apoptotic, anti-thrombotic, anti-inflammatory, or anti-infectious functions. Clinical data demonstrate that HDL cholesterol levels decrease rapidly during sepsis and that these low levels are correlated with morbi-mortality. Experimental studies emphasized notable structural and functional modifications of HDL particles in inflammatory states, including sepsis. Finally, HDL infusion in animal models of sepsis improved survival and provided a global endothelial protective effect. These clinical and experimental studies reinforce the potential of HDL therapy in human sepsis. In this review, we will detail the different effects of HDLs that may be relevant under inflammatory conditions and the lipoprotein changes during sepsis and we will discuss the potentiality of HDL therapy in sepsis.

【 授权许可】

Unknown